HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
NTRA [NASD]
Natera, Inc.
Healthcare | Diagnostics & Research | USA
statements
Index- P/E- EPS (ttm)-5.88 Insider Own1.60% Shs Outstand95.58M Perf Week34.80%
Market Cap3.17B Forward P/E- EPS next Y-5.04 Insider Trans25.13% Shs Float92.52M Perf Month2.28%
Income-546.50M PEG- EPS next Q-1.50 Inst Own94.40% Short Float9.03% Perf Quarter-40.68%
Sales667.30M P/S4.75 EPS this Y-83.70% Inst Trans-5.96% Short Ratio2.99 Perf Half Y-65.36%
Book/sh5.67 P/B6.87 EPS next Y3.00% ROA-48.10% Target Price86.70 Perf Year-55.73%
Cash/sh9.24 P/C4.22 EPS next 5Y- ROE-97.00% 52W Range26.10 - 129.09 Perf YTD-58.27%
Dividend- P/FCF- EPS past 5Y-21.80% ROI-47.70% 52W High-69.81% Beta1.29
Dividend %- Quick Ratio4.10 Sales past 5Y24.10% Gross Margin46.80% 52W Low49.31% ATR3.39
Employees2670 Current Ratio4.20 Sales Q/Q27.40% Oper. Margin-81.30% RSI (14)55.04 Volatility11.09% 10.50%
OptionableYes Debt/Eq0.61 EPS Q/Q-96.90% Profit Margin-81.90% Rel Volume0.45 Prev Close35.93
ShortableYes LT Debt/Eq0.52 EarningsMay 05 AMC Payout- Avg Volume2.80M Price38.97
Recom1.70 SMA2012.02% SMA503.07% SMA200-52.21% Volume1,298,540 Change8.46%
Apr-25-22Initiated Stephens Overweight $54
Mar-08-22Initiated Goldman Buy $90
Jan-06-22Resumed Piper Sandler Overweight $110
Oct-15-21Resumed Cowen Outperform $150
Jun-15-21Initiated Raymond James Mkt Perform
May-25-21Initiated Wells Fargo Overweight $110
Jan-28-21Initiated Truist Buy $143
Oct-08-20Initiated BTIG Research Buy $90
Sep-28-20Initiated Morgan Stanley Overweight $80
Sep-17-20Initiated SVB Leerink Outperform $75
Jun-10-20Resumed Piper Sandler Overweight $56 → $63
May-07-20Upgrade JP Morgan Neutral → Overweight $32 → $45
Oct-05-18Initiated JP Morgan Neutral $26
Jul-05-18Reiterated Piper Jaffray Overweight $18 → $21
Aug-07-17Reiterated Morgan Stanley Overweight $18 → $13
Nov-10-16Reiterated The Benchmark Company Buy $16 → $20
May-23-16Reiterated The Benchmark Company Buy $15 → $16
May-11-16Reiterated The Benchmark Company Buy $14 → $15
Apr-19-16Initiated The Benchmark Company Buy $14
Sep-28-15Upgrade Wedbush Neutral → Outperform
May-16-22 07:30AM  
Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera
PR Newswire
May-10-22 02:03PM  
Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?
Simply Wall St.
May-05-22 06:35PM  
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Zacks -7.36%
04:05PM  
Natera Reports First Quarter 2022 Financial Results
PR Newswire
May-04-22 08:28AM  
Heres Why Baron Funds Disposed its Natera (NTRA) Position
Insider Monkey
May-02-22 08:03AM  
Natera Announces First Quarter 2022 Earnings Conference Call
PR Newswire +6.95%
May-01-22 06:12PM  
Law firm files class action against pharma company Natera - statement
Reuters
Apr-28-22 03:02PM  
Earnings Preview: Natera (NTRA) Q1 Earnings Expected to Decline
Zacks
Apr-26-22 07:33AM  
Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)
PR Newswire -5.70%
Apr-19-22 07:33AM  
Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease
PR Newswire
Apr-17-22 01:21PM  
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Natera To Contact Him Directly To Discuss Their Options
ACCESSWIRE
Apr-15-22 05:44PM  
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Natera To Contact Him Directly To Discuss Their Options
ACCESSWIRE
Apr-13-22 07:33AM  
Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection
PR Newswire
Apr-11-22 07:33AM  
Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting
PR Newswire
Apr-07-22 07:33AM  
Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test
PR Newswire
Apr-06-22 07:33AM  
Natera Adds to Organ Health Medical Affairs Leadership Team
PR Newswire
Apr-01-22 07:33AM  
Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 Infection
PR Newswire +5.46%
Mar-28-22 07:33AM  
Natera Listed as One of World's Most Innovative Health Companies by Fast Company
PR Newswire
Mar-23-22 06:00AM  
UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
GlobeNewswire -6.59%
Mar-22-22 08:30AM  
10 Healthcare Stocks to Buy Today According to Steven Cohens Point72 Asset Management
Insider Monkey +5.96%
07:33AM  
New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology
PR Newswire
Mar-21-22 08:50PM  
3 Strong Buy Stocks Drawing Interest From Insiders
TipRanks
07:33AM  
Natera Announces Updated Signatera MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US Trial
PR Newswire
Mar-18-22 07:50AM  
Should You Buy Natera Stock Despite the Scathing Short-Seller Report From Hindenburg?
Motley Fool +5.65%
Mar-16-22 11:04AM  
Roelof Botha, Lead Independent Director of Natera Board, Makes $5 Million Investment in Natera
PR Newswire +15.50%
Mar-15-22 11:20AM  
CareDx Wins $44.9 Million in Damages in False Advertising Trial
Investing.com -15.52%
01:14AM  
Jury Finds CareDx and Natera Engaged in False Advertising
PR Newswire
Mar-14-22 08:06PM  
CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
GlobeNewswire -7.93%
07:25AM  
Natera to pay executive salaries in stock the rest of 2022, citing 'confidence' in outlook despite sharp stock selloff
MarketWatch
07:00AM  
Natera Executives and Board to Take Pay in Stock Instead of Cash
PR Newswire
Mar-11-22 07:30AM  
Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study
PR Newswire -8.52%
Mar-09-22 06:41PM  
Natera to Host Special Investor Call in Response to Misleading Short Seller Report
PR Newswire -32.79%
03:04PM  
Natera loses more than $1.7 billion in market cap, even after company calls Hindenburg report 'misleading'
MarketWatch
02:33PM  
NATERA RESPONDS TO MISLEADING SHORT SELLER REPORT
PR Newswire
07:55AM  
Natera Plunges After Hindenburg Short Report
Investing.com
Feb-24-22 06:50PM  
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Zacks +7.36%
04:05PM  
Natera Reports Fourth Quarter and Full Year 2021 Financial Results
PR Newswire
Feb-22-22 05:35PM  
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
Zacks
Feb-17-22 05:48PM  
Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call
PR Newswire -8.11%
03:02PM  
Analysts Estimate Natera (NTRA) to Report a Decline in Earnings: What to Look Out for
Zacks
08:35AM  
Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera Kidney Test
PR Newswire
Feb-15-22 08:35AM  
Natera to Participate in Upcoming Investor Conferences
PR Newswire
Feb-07-22 05:38PM  
Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ...
GuruFocus.com
01:38PM  
Silvant Capital Management LLC Buys Netflix Inc, Pfizer Inc, Natera Inc, Sells Visa Inc, ...
GuruFocus.com
11:17AM  
Shareholders have faith in loss-making Natera (NASDAQ:NTRA) as stock climbs 6.5% in past week, taking five-year gain to 644%
Simply Wall St.
Feb-03-22 05:38PM  
Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ...
GuruFocus.com
Feb-02-22 06:48PM  
Did Hedge Funds Get Natera Inc (NTRA) Right?
Insider Monkey
Jan-28-22 01:38PM  
James Investment Research Inc Buys iShares TIPS Bond ETF, Jabil Inc, iShares 0-5 Year TIPS Bond ...
GuruFocus.com +5.77%
11:07AM  
Alger Remains Optimistic in Natera (NTRA) Despite Being Part of its Detractor List
Insider Monkey
Jan-25-22 01:38PM  
SWS Partners Buys Abbott Laboratories, Cognizant Technology Solutions Corp, American Homes 4 ...
GuruFocus.com
Jan-22-22 02:22PM  
Landmark CIRCULATE-Japan Study Shows Natera's Signatera MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer
PR Newswire
Jan-21-22 05:38PM  
Allworth Financial LP Buys iShares Core S&P 500 ETF, Vanguard Mid-Cap Growth ETF, ...
GuruFocus.com
Jan-20-22 08:33AM  
Landmark SMART Study Demonstrates High Accuracy of Nateras Panorama® NIPT for 22q11.2 Deletion Screening
Business Wire
Jan-19-22 08:33AM  
Natera to Present Latest Signatera MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call
PR Newswire
Jan-06-22 08:33AM  
Natera Announces Expansion Into Early Cancer Detection and Screening
Business Wire
Jan-04-22 08:33AM  
Natera to Webcast Live Presentation at the 40th Annual J.P. Morgan Healthcare Conference
PR Newswire
Jan-03-22 08:33AM  
Signatera Wins Fierce Life Sciences Innovation Award
PR Newswire
Dec-24-21 12:38AM  
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...
GuruFocus.com
Dec-18-21 09:38PM  
Wanger Advisors Trust Buys Bill.com Holdings Inc, Avalara Inc, Etsy Inc, Sells Teradyne Inc, ...
GuruFocus.com
03:38AM  
Jnl Series Trust Buys Palo Alto Networks Inc, Natera Inc, Hologic Inc, Sells Pinterest Inc, ...
GuruFocus.com
12:38AM  
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...
GuruFocus.com
Dec-17-21 11:38PM  
VY(R) Invesco Oppenheimer Global Portfolio Buys Analog Devices Inc, Splunk Inc, Danaher Corp, ...
GuruFocus.com +7.18%
Dec-14-21 11:38PM  
VanEck Biotech ETF Buys Icon PLC, Bio-Techne Corp, Natera Inc, Sells , Neurocrine Biosciences ...
GuruFocus.com
Dec-13-21 04:38PM  
Invesco V.I. Global Fund Buys Analog Devices Inc, Dassault Systemes SE, Splunk Inc, Sells , ...
GuruFocus.com
Dec-09-21 09:03AM  
Natera Presents Latest Signatera MRD Data in Breast Cancer at SABCS 2021
PR Newswire -5.19%
Dec-07-21 08:34PM  
Should I Avoid Natera Inc (NTRA)?
Insider Monkey +7.30%
04:38PM  
Mutual of America VIP Small-Cap Growth Portfolio Buys Zuora Inc, Ollie's Bargain Outlet ...
GuruFocus.com
Dec-04-21 02:29PM  
10 Best Healthcare Stocks to Buy According to Greg Martinezs Parkman Healthcare Partners
Insider Monkey
Nov-29-21 11:32AM  
10 Biotech and Pharma Stocks to Buy According to Billionaire Steve Cohen
Insider Monkey
Nov-19-21 09:00AM  
Natera's Panorama SMART Study Results Accepted for Publication by the American Journal of Obstetrics and Gynecology (AJOG)
PR Newswire
Nov-15-21 10:44AM  
Notable Natera Insider Makes $2.8M Sale
Benzinga
Nov-11-21 02:11PM  
Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring
Benzinga +5.80%
11:52AM  
Medicare Publishes Final Local Coverage Determination for Pan-Cancer Immunotherapy Monitoring with Natera's Signatera MRD Test
PR Newswire
Nov-08-21 02:11PM  
Was The Smart Money Right About Natera Inc (NTRA)?
Insider Monkey
12:45PM  
Baron Funds: Natera (NTRA) has a Long Runway for Growth with Expanding Margins and Profitability
Insider Monkey
11:25AM  
Natera (NASDAQ:NTRA) Has Debt But No Earnings; Should You Worry?
Simply Wall St.
Nov-05-21 09:00AM  
Natera Inc (NTRA) Q3 2021 Earnings Call Transcript
Motley Fool
Nov-04-21 08:56PM  
Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:05PM  
Natera Reports Third Quarter 2021 Financial Results
PR Newswire
11:08AM  
Chief Operating Officer Of Natera Trades $1.5M In Company Stock
Benzinga
Nov-03-21 09:35AM  
Should You Buy Natera (NTRA) Ahead of Earnings?
Zacks
08:33AM  
Natera Validates Prospera With Quantification in Multi-Site, Prospective Trifecta Study
PR Newswire
Nov-02-21 11:40AM  
CEO And President Of Natera Trades $840K In Company Stock
Benzinga
Oct-28-21 03:05PM  
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks
09:08AM  
Wall Street Analysts Believe Natera (NTRA) Could Rally 27%: Here's is How to Trade
Zacks
08:33AM  
Natera Announces Third Quarter 2021 Earnings Conference Call
PR Newswire
Oct-19-21 09:25AM  
11 Best Genomic Stocks to Buy Now
Insider Monkey
Oct-18-21 08:33AM  
Natera Expands Organ Health Business With Commercial Launch of the Prospera Lung Transplant Assessment Test
PR Newswire
Oct-13-21 11:31AM  
Chief Operating Officer Of Natera Trades $230K In Company Stock
Benzinga
Oct-11-21 08:33AM  
Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management
PR Newswire
Oct-06-21 08:33AM  
Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation
PR Newswire
Oct-04-21 11:23AM  
Hedge Funds Are Piling Into Natera Inc (NTRA)
Insider Monkey
Sep-29-21 12:30AM  
Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents
PR Newswire
Sep-17-21 08:33AM  
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma
PR Newswire
Sep-13-21 11:09AM  
CEO And President Of Natera Trades $12.01 Million In Company Stock
Benzinga
Sep-09-21 08:33AM  
Natera Launches Prospera Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation
PR Newswire
Sep-07-21 06:03AM  
Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
PR Newswire
Aug-31-21 08:30AM  
Natera Announces the Validation and Launch of the Prospera Heart Transplant Assessment Test
PR Newswire
Aug-10-21 09:38AM  
New Strong Sell Stocks for August 10th
Zacks -7.98%
09:03AM  
Natera to Participate in Upcoming Investor Conferences
PR Newswire
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rabinowitz MatthewEXECUTIVE CHAIRMANMay 12Buy28.74219,8206,317,762420,000May 16 07:15 AM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERApr 22Sale36.1445816,55380,935Apr 25 09:05 PM
Chapman Steven LeonardCEO AND PRESIDENTApr 22Sale36.1489432,31063,122Apr 25 09:05 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERApr 22Sale36.1432511,746143,358Apr 25 09:05 PM
Schueren Robert AlanCHIEF OPERATING OFFICERApr 22Sale36.1457720,8533,919Apr 25 09:05 PM
Schueren Robert AlanCHIEF OPERATING OFFICERApr 08Sale41.911,99983,7793,352Apr 11 08:05 PM
Chapman Steven LeonardCEO AND PRESIDENTApr 04Sale43.091,55967,17762,242Apr 05 08:05 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERMar 28Sale39.6368627,185143,039Mar 29 08:05 PM
Sheena JonathanCO-FOUNDERMar 28Sale39.631345,310564,348Mar 29 08:05 PM
Schueren Robert AlanCHIEF OPERATING OFFICERMar 28Sale39.631,38254,7671,367Mar 29 08:05 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 28Sale39.6391536,26080,249Mar 29 08:05 PM
Chapman Steven LeonardCEO AND PRESIDENTMar 28Sale39.632,605103,23360,676Mar 29 08:05 PM
Chapman Steven LeonardCEO AND PRESIDENTMar 23Sale40.601,68268,29158,098Mar 24 08:30 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 23Sale40.6043617,70378,873Mar 24 08:30 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERMar 23Sale40.6045518,474142,361Mar 24 08:30 PM
Sheena JonathanCO-FOUNDERMar 23Sale40.601385,603564,035Mar 24 08:30 PM
BOTHA ROELOFDirectorMar 16Buy32.72153,0005,005,4111,291,584Mar 18 07:34 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANMar 14Option Exercise2.66160,000425,104678,838Mar 16 08:05 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERMar 10Sale42.1688437,269141,923Mar 11 09:30 PM
Chapman Steven LeonardCEO AND PRESIDENTMar 10Sale42.161,14748,35856,473Mar 11 09:30 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERMar 10Sale42.161,19750,46678,231Mar 11 09:30 PM
Sheena JonathanCO-FOUNDERMar 10Sale42.1669429,259563,718Mar 11 09:30 PM
Sheena JonathanCO-FOUNDERMar 09Option Exercise1.1421,95025,045562,120Mar 11 09:30 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANMar 09Option Exercise2.6690,000239,121516,019Mar 11 09:30 PM
Sheena JonathanCO-FOUNDERFeb 07Option Exercise1.1420,00022,820544,483Feb 09 08:05 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERJan 24Sale59.941,33880,205138,047Jan 25 08:05 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERJan 24Sale59.951,27576,43170,992Jan 25 08:05 PM
Schueren Robert AlanCHIEF OPERATING OFFICERJan 24Sale59.952,378142,54926,955Jan 25 08:05 PM
Chapman Steven LeonardCEO AND PRESIDENTJan 24Sale59.953,686220,96155,323Jan 25 08:05 PM
Sheena JonathanCO-FOUNDERJan 24Sale59.9520812,469524,483Jan 25 08:05 PM
Sheena JonathanCO-FOUNDERJan 19Option Exercise1.1425,00028,525524,119Jan 20 08:05 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERJan 14Option Exercise10.0080,385803,692136,809Jan 20 08:05 PM
Schueren Robert AlanCHIEF OPERATING OFFICERJan 10Sale74.452,116157,54524,754Jan 11 07:01 PM
Sheena JonathanCO-FOUNDERJan 07Option Exercise1.1420,00022,820499,119Jan 11 07:02 PM
Chapman Steven LeonardCEO AND PRESIDENTJan 05Sale82.614,995412,63751,911Jan 06 08:01 PM
Chapman Steven LeonardCEO AND PRESIDENTJan 03Option Exercise21.4927,958600,94776,698Jan 04 09:28 PM
Sheena JonathanCO-FOUNDERJan 03Option Exercise1.1420,00022,820479,119Jan 04 09:29 PM
Chapman Steven LeonardCEO AND PRESIDENTJan 03Sale88.2729,1672,574,56447,531Jan 04 09:28 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 28Sale91.3491483,48567,688Dec 29 06:06 PM
Chapman Steven LeonardCEO AND PRESIDENTDec 28Sale91.342,604237,84945,615Dec 29 06:08 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERDec 28Sale91.3468562,56856,424Dec 29 06:09 PM
Sheena JonathanCO-FOUNDERDec 28Sale91.3420218,451459,119Dec 29 06:12 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 28Sale91.341,382126,23222,885Dec 29 06:11 PM
Sheena JonathanCO-FOUNDERDec 23Sale92.9920418,970458,874Dec 27 07:07 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERDec 23Sale93.0044741,56955,746Dec 27 07:05 PM
Chapman Steven LeonardCEO AND PRESIDENTDec 23Sale93.001,657154,09743,036Dec 27 07:04 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 23Sale93.0042939,89566,310Dec 27 07:03 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 21Option Exercise13.015,00065,05026,517Dec 23 08:16 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 21Sale92.987,000650,86062,283Dec 23 08:16 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 21Sale92.975,000464,87221,517Dec 23 08:16 PM
Sheena JonathanCO-FOUNDERDec 10Sale91.331,05095,896458,623Dec 13 07:03 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 10Sale91.331,196109,23165,662Dec 13 07:18 PM
Chapman Steven LeonardCEO AND PRESIDENTDec 10Sale91.331,145104,57341,386Dec 13 07:13 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERDec 10Sale91.3389982,10655,301Dec 13 07:11 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 08Option Exercise13.011,28116,66621,517Dec 13 07:06 PM
Schueren Robert AlanCHIEF OPERATING OFFICERDec 07Sale91.994,411405,77720,236Dec 07 09:11 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERDec 07Sale91.993,151289,86754,429Dec 07 09:10 PM
Chapman Steven LeonardCEO AND PRESIDENTDec 07Sale91.994,726434,75440,235Dec 07 09:09 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERDec 07Sale91.993,501322,06463,837Dec 07 09:08 PM
Chapman Steven LeonardCEO AND PRESIDENTDec 01Option Exercise13.537,21997,68542,805Dec 03 09:02 PM
Chapman Steven LeonardCEO AND PRESIDENTDec 01Sale90.807,219655,45435,586Dec 03 09:02 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERNov 10Sale111.1425,4952,833,42158,588Nov 12 09:30 PM
ROSENMAN HERMDirectorNov 08Option Exercise2.6644,503118,24095,778Nov 09 03:25 PM
ROSENMAN HERMDirectorNov 08Sale29.3744,5031,307,20251,275Nov 09 03:25 PM
Chapman Steven LeonardCEO AND PRESIDENTNov 01Option Exercise13.755,13670,59640,721Nov 01 09:02 PM
Schueren Robert AlanCHIEF OPERATING OFFICERNov 01Option Exercise13.016,00078,06027,897Nov 03 07:32 PM
Schueren Robert AlanCHIEF OPERATING OFFICERNov 01Sale120.0012,0001,440,01015,897Nov 03 07:32 PM
Chapman Steven LeonardCEO AND PRESIDENTNov 01Sale115.646,652769,22135,586Nov 01 09:02 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANOct 14Sale112.1912213,687582,494Oct 15 07:02 PM
Schueren Robert AlanCHIEF OPERATING OFFICEROct 12Option Exercise13.011,28116,66623,178Oct 14 07:29 PM
Schueren Robert AlanCHIEF OPERATING OFFICEROct 08Sale117.081,986232,52125,213Oct 12 07:05 PM
Chapman Steven LeonardCEO AND PRESIDENTOct 05Sale110.911,608178,34337,103Oct 05 09:31 PM
Chapman Steven LeonardCEO AND PRESIDENTOct 04Option Exercise16.644,16869,35642,879Oct 05 09:31 PM
Chapman Steven LeonardCEO AND PRESIDENTOct 04Sale107.6012,8961,387,5730Oct 05 09:31 PM
Chapman Steven LeonardCEO AND PRESIDENTOct 04Sale108.656,653722,86438,711Oct 05 09:31 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSep 28Sale109.7271077,89951,330Sep 29 07:42 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERSep 28Sale109.72947103,90184,083Sep 29 07:43 PM
Chapman Steven LeonardCEO AND PRESIDENTSep 28Sale109.722,698296,01238,071Sep 29 07:50 PM
Schueren Robert AlanCHIEF OPERATING OFFICERSep 28Sale109.711,431157,00223,215Sep 29 07:50 PM
Sheena JonathanCO-FOUNDERSep 28Sale109.7120922,930457,381Sep 29 07:52 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERSep 27Sale114.8425,0002,871,03585,030Sep 29 07:43 PM
Chapman Steven LeonardCEO AND PRESIDENTSep 24Sale119.0426,9143,203,95935,586Sep 24 09:32 PM
Chapman Steven LeonardCEO AND PRESIDENTSep 23Sale125.671,649207,23062,500Sep 24 09:32 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERSep 23Sale125.6742753,661107,738Sep 24 09:29 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSep 23Sale125.6744656,04950,676Sep 24 09:27 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANSep 23Sale125.6715919,982582,309Sep 24 09:21 PM
Sheena JonathanCO-FOUNDERSep 23Sale125.6720425,637457,143Sep 24 09:19 PM
Chapman Rowan EDirectorSep 17Option Exercise32.155,500176,82510,356Sep 21 07:17 PM
Chapman Rowan EDirectorSep 17Sale120.775,500664,2494,856Sep 21 07:17 PM
Chapman Steven LeonardCEO AND PRESIDENTSep 10Option Exercise15.5371,8241,115,634132,666Sep 10 09:37 PM
Chapman Steven LeonardCEO AND PRESIDENTSep 10Sale119.6510,1421,213,47912,896Sep 10 09:37 PM
Chapman Steven LeonardCEO AND PRESIDENTSep 10Sale119.7280,8269,676,56360,842Sep 10 09:37 PM
Brophy Michael BurkesCHIEF FINANCIAL OFFICERSep 10Sale119.536,188739,642107,088Sep 13 08:33 PM
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICERSep 10Sale119.53890106,38050,229Sep 13 08:34 PM
Rabinowitz MatthewEXECUTIVE CHAIRMANSep 10Sale119.53876104,707582,068Sep 13 08:34 PM
Sheena JonathanCO-FOUNDERSep 10Sale119.531,030123,114456,892Sep 13 08:36 PM
Schueren Robert AlanCHIEF OPERATING OFFICERSep 10Sale119.536,278750,40028,119Sep 13 08:35 PM
Cozzens Todd CDirectorSep 02Option Exercise10.0424,480245,69837,470Sep 03 09:49 PM
Cozzens Todd CDirectorSep 02Sale121.7424,2712,954,86017,963Sep 03 09:49 PM
Sheena JonathanCO-FOUNDERSep 01Option Exercise9.5513,539129,309469,169Sep 01 09:06 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.